Graphite Bio, Inc.(GRPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GRPH Graphite Bio, Inc.

Post-Mkt 12-23 17:45:18 EST

15.05

+0.00

0.00%

High15.05	Low15.05	Vol0.00
Open15.05	D1 Closing15.05	Amplitude0.00%
Mkt Cap876.47M	Tradable Cap251.01M	Total Shares58.24M
T/O1.03M	T/O Rate0.00%	Tradable Shares16.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GRPH","market":"US","secType":"STK","nameCN":"Graphite Bio, Inc.","latestPrice":15.05,"timestamp":1711051200000,"preClose":15.05,"halted":8,"volume":0,"delay":0,"floatShares":16678630,"shares":58236926,"eps":-2.186278,"marketStatus":"Post-Mkt","change":0,"latestTime":"12-23 17:45:18 EST","open":15.05,"high":15.05,"low":15.05,"amount":1032198.4924146,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.186278,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766538000000},"marketStatusCode":4,"symbolChange":{"newSymbol":"LENZ","executeDate":"2024-03-22"},"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":15.05,"volumeRatio":0},"requestUrl":"/m/hq/s/GRPH","defaultTab":"news","newsList":[{"id":"2421070576","title":"BRIEF-LENZ Therapeutics Announces Completion of Merger with Graphite Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2421070576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2421070576?lang=en_us&edition=fundamental","pubTime":"2024-03-22 05:17","pubTimestamp":1711055826,"startTime":"0","endTime":"0","summary":"March 21 (Reuters) - Graphite Bio Inc   :   * LENZ THERAPEUTICS:  APPOINTED DAN CHEVALLARD AS CFO , EFFECTIVE MARCH 21, 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AS","BK4539","BK4202","BK4139","GRPH"],"gpt_icon":0},{"id":"2421074946","title":"Press Release: LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2421074946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2421074946?lang=en_us&edition=fundamental","pubTime":"2024-03-22 04:30","pubTimestamp":1711053000,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress. -- LENZ Therapeutics to debut on Nasdaq under the ticker symbol \"LENZ\" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia --. Previously, both LNZ100 and LNZ101 have demonstrated rapid onset and long duration of near vision improvement as well as an ability to be used across a wide age range of presbyopes with a broad refractive range while avoiding blurry distance vision. In the positive Phase 2 INSIGHT trial , both LZN100 and LNZ101 achieved their primary endpoint of three-lines or greater near vision improvement without losing one or more lines in distance vision at one hour post-treatment, with 71%  and 56%  of treated patients achieving th","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4503","LU0210637038.USD","SG9999005177.SGD","SG9999002414.USD","SG9999013460.SGD","SGXZ58947870.SGD","LU0048573645.USD","BK4085","BK4588","BK4539","IE00BMG7P694.USD","SG9999002679.SGD","SG9999013478.USD","SG9999014484.SGD","BK4139","BK4581","SG9999004360.SGD","BK4548","IE00BD4GTT62.SGD","BK4566","BK4097","LU0251143029.SGD","LU0532188223.SGD","GRPH","SG9999002620.SGD","IE0034224299.USD","SG9999002604.SGD","INAQU","IE00BMG7P587.USD","IE00BD4GTV84.USD","SG9999013486.USD","BK4535","IE00BMG7P926.USD","LU2065732104.USD","SG9999006266.SGD","D","SE","BK4551","SG9999001135.SGD","SG9999002406.SGD","PRGS","BK4585","SG9999014492.USD","BK4208","BK4554","IE00BD4GTW91.USD","NQmain"],"gpt_icon":0},{"id":"2418012053","title":"Stocks to Watch: Graphite Bio, Revance Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2418012053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2418012053?lang=en_us&edition=fundamental","pubTime":"2024-03-09 07:54","pubTimestamp":1709942040,"startTime":"0","endTime":"0","summary":"Graphite Bio on Friday said it would pay a special dividend tied to its merger with Lenz Therapeutics. Shares of the biotechnology company climbed 10% to $3.46 in after-hours trading.Revance Therapeutics said its chief executive bought additional shares in the company. Shares of the biotechnology company rose 2.7% to $6.17 in after-hours trading.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","BK4588","BK4585","BK4539","GRPH","RVNC","BK4007"],"gpt_icon":0},{"id":"2418829014","title":"Graphite Bio Shares Pop 14% On Special Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2418829014","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2418829014?lang=en_us&edition=fundamental","pubTime":"2024-03-09 07:15","pubTimestamp":1709939700,"startTime":"0","endTime":"0","summary":"Shares of Graphite Bio popped Friday after the company said it would pay a special dividend connected with its merger.The stock was up 14% to $3.59 in after-hours trading, following a 0.3% rise at Friday's close. Shares are up 20% this year as of the close.The South San Francisco, Calif.-based company said it expected the special dividend to be $1.03 a share.The exact amount of the dividend will be set after certain cash deductions, but the total value paid will not exceed $60 million, Graphite said.The dividend is linked to Graphite's previously announced merger with Lenz Therapeutics. The company said it expects the deal to close March 21 following a shareholder vote March 14.The companies said they were targeting a deal close in the first quarter of 2024 when they announced the tie-up in November.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRPH","BK4539","BK4139"],"gpt_icon":0},{"id":"2418016984","title":"Graphite Bio to Pay Special Dividend Linked to Lenz Therapeutics Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2418016984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2418016984?lang=en_us&edition=fundamental","pubTime":"2024-03-09 06:16","pubTimestamp":1709936160,"startTime":"0","endTime":"0","summary":"Graphite Bio will pay a special dividend connected to its merger with Lenz Therapeutics.The South San Francisco, Calif.-based gene editing company said Friday it estimated the special dividend will be $1.03 a share.The total value of the special dividend won't exceed $60 million, subject to certain adjustments in the merger agreement, according to Graphite Bio. The exact amount of the dividend will be determined after deducting certain cash amounts as outlined in the merger agreement.The payment of the dividend is conditioned on the merger closing. Graphite Bio shareholders will vote on the deal at a March 14 meeting, with closing expected March 21.Graphite Bio and Lenz said in November they planned to merge in an all-stock deal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRPH","BK4539"],"gpt_icon":0},{"id":"2418150620","title":"BRIEF-Graphite Bio Inc Special Dividend Estimated To Be $1.03 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2418150620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2418150620?lang=en_us&edition=fundamental","pubTime":"2024-03-09 06:07","pubTimestamp":1709935622,"startTime":"0","endTime":"0","summary":"March 8 (Reuters) - Graphite Bio Inc   :   * GRAPHITE BIO INC: SPECIAL DIVIDEND ESTIMATED TO BE $1.03 PER SHARE   * GRAPHITE BIO INC:  DECLARES SPECIAL DIVIDEND ESTIMATED TO BE $1.03 PER SHARESource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRPH","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://graphitebio.com","stockEarnings":[{"period":"1week","weight":-0.3239},{"period":"1month","weight":-0.3239},{"period":"3month","weight":-0.3239},{"period":"6month","weight":-0.3239},{"period":"1year","weight":-0.3239},{"period":"ytd","weight":-0.3239}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.","exchange":"NASDAQ","name":"Graphite Bio, Inc.","nameEN":"Graphite Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Graphite Bio, Inc.(GRPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Graphite Bio, Inc.(GRPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Graphite Bio, Inc.,GRPH,Graphite Bio, Inc.股票,Graphite Bio, Inc.股票老虎,Graphite Bio, Inc.股票老虎国际,Graphite Bio, Inc.行情,Graphite Bio, Inc.股票行情,Graphite Bio, Inc.股价,Graphite Bio, Inc.股市,Graphite Bio, Inc.股票价格,Graphite Bio, Inc.股票交易,Graphite Bio, Inc.股票购买,Graphite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Graphite Bio, Inc.(GRPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Graphite Bio, Inc.(GRPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction